Kepler Capital Reaffirms Their Sell Rating on TGS (0MSJ)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Roger covers the Energy sector, focusing on stocks such as Subsea 7, Saipem SpA, and TGS. According to TipRanks, Roger has an average return of 15.5% and a 66.81% success rate on recommended stocks.
Currently, the analyst consensus on TGS is a Hold with an average price target of NOK100.50.
0MSJ market cap is currently NOK15.44B and has a P/E ratio of 48.53.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
32 minutes ago
- Business Insider
Tesla Stock (NASDAQ:TSLA) Slides as European Tesla Buyers Find Options Curtailed
Interested in a new Tesla (TSLA) electric vehicle? Live in Europe? Then I have some bad news for you today, as your shopping options got just a little narrower. Two models of Tesla vehicles are apparently no longer available for order in Europe. Leaving money on the table seldom sits well with shareholders, and today proved no exception. Shares slid nearly 2% in Thursday morning's trading. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Tesla will no longer be taking orders for the Model S and the Model X in Europe, reports note. Investigations of several countries' Tesla sites—including Italy, France, Germany and more—confirmed that the S and X were nowhere to be seen. Only 'inventory' versions of these cars were available for purchase. However, the Model 3 and the Model Y were both unfazed by the change, and were still available for order with full configuration options. Reports suggest that the Model S and the Model X are considered 'other' models at Tesla, along with the Cybertruck. And given that Tesla only delivered 10,394 of those 'other' models in the latest quarter, this may be a sign that Tesla is no longer supplying what people do not want. Other reports, however, note that this kind of thing has happened before. When lead time for orders grows too long, Tesla has been known to shut down ordering on certain models to let production catch up. Now With New Lighting! Other reports note that Tesla has brought out a new feature that customers have been eagerly anticipating for some time now. For cars with interior ambient lighting, the new Version 2025.26+ Software Update will bring out an exciting new feature: 'Sync Accent Lights w/Music.' Available in the Tesla Toybox, the update basically turns your car's interior into a sweet dance party. More specifically, it takes the car's interior lighting and allows it to both pulse rhythmically and change color according to the music being played. This is not at all a performance feature. But in terms of sheer gee-whiz factor, it is hard to beat an interior lighting scheme that will adjust itself according to your musical preferences. That might be the kind of thing that tilts some customers into a buying decision, and Tesla could use more buyers right now. Is Tesla a Buy, Hold or Sell? Turning to Wall Street, analysts have a Hold consensus rating on TSLA stock based on 14 Buys, 14 Holds, and eight Sells assigned in the past three months, as indicated by the graphic below. After a 47.12% rally in its share price over the past year, the average TSLA price target of $310.84 per share implies 0.45% downside risk.
Business Insider
32 minutes ago
- Business Insider
FireFly Metals (MNXMF) Receives a Buy from Shaw and Partners
Shaw and Partners analyst Peter Kormendy maintained a Buy rating on FireFly Metals today and set a price target of A$1.65. The company's shares closed yesterday at $0.71. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Kormendy covers the Basic Materials sector, focusing on stocks such as AIC Mines Limited, FireFly Metals, and Lunnon Metals Limited. According to TipRanks, Kormendy has an average return of 0.0% and a 35.71% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for FireFly Metals with a $1.07 average price target, a 51.24% upside from current levels. In a report released on July 17, MA Financial Group also maintained a Buy rating on the stock with a A$1.40 price target.
Business Insider
32 minutes ago
- Business Insider
Is MRNA Stock (MRNA) a Buy Ahead of Q2 Earnings?
Drug giant Moderna (MRNA) is set to release its Q2 earnings report this week. This has some investors wondering whether it is a good idea to buy shares of MRNA beforehand. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. What Wall Street Expects Wall Street expects MRNA to reveal a quarterly loss of $2.99 per share, indicating an increase of 10.2% compared to the same period last year. Analysts also forecast revenues of $127.17 million, representing a decline of 47.2% year-over-year. Will MRNA be able to beat these estimates? As can be seen below, it has a strong track record of doing just that in recent quarters. Key Insights Ahead of Earnings In the first quarter, MRNA reported total revenues of $108 million, reflecting a 35% decrease year-over-year, attributed to the seasonal nature of the respiratory vaccines and lower vaccination rates. It reported a net loss of $1 billion for Q1 2025, an improvement from a $1.2 billion loss in Q1 2024. Net product sales were $86 million, mainly from COVID vaccine sales, with the U.S. contributing about one-third of these sales. This was a decline from the previous year due to the transition of COVID into routine seasonal vaccination patterns. It also announced the expansion of its oncology portfolio with the addition of the Checkpoint medicine program, showing early but encouraging data. In Q2, Moderna is likely to have generated a major portion of its revenues from selling its COVID-19 vaccine, Spikevax. The vaccine sales are likely to be pegged at $59 million, implying a significant decline from the year-ago level due to lower demand. However, the European Commission recently granted marketing authorization for the updated formulation of Spikevax. Analysts also expect minimal product sales of the company's RSV vaccine mResvia, which received FDA approval last year. mResvia sales are expected to be $2 million, far below sales of competing RSV vaccines, Arexvy, marketed by GSK (GSK), and Pfizer's (PFE) Abrysvo. Investors will also want to learn more about Intismeran autogene, a personalized cancer therapy which is being developed in collaboration with Merck (MRK). Longer-term, this could be a boost to the group's currently ailing share price. Is MRNA a Good Stock to Buy Now? On TipRanks, MRNA has a Hold consensus based on 3 Buy, 13 Hold and 3 Sell ratings. Its highest price target is $198. MRNA stock's consensus price target is $48.14, implying a 49.74% upside.
